PDF(Pubmed)
Abstract：
UNASSIGNED: Migraine is a global public health concern, affecting both social and individual well-being. Calcitonin gene-related peptide (CGRP), a crucial neuropeptide, holds important research value in understanding migraine pathogenesis. CGRP receptor antagonists and monoclonal antibodies that target CGRP or its receptors have shown efficacy in reducing migraine frequency and severity, presenting a promising therapeutic approach. This study aimed to conduct a comprehensive bibliometric analysis to analyze the current state, research trends, and future directions of CGRP in migraine.
UNASSIGNED: Bibliometric tools including CiteSpace, VOSviewer, etc., were utilized to extract and summarize publications related to CGRP in migraine from the Web of Science Core Collection Database (WOSCC) between 2004 and 2023, as of December 31, 2023. The analysis focused on trends in annual publications, leading countries/regions and institutions, prominent journals and references, influential authors, and high-frequency keywords in the field.
UNASSIGNED: A total of 1,821 articles and reviews involving 5,180 authors from 1,315 organizations across 64 countries were included in the study. These publications were distributed across 362 journals and accumulated 56,999 citations by December 31, 2023. An increasing trend was observed in annual publications on CGRP in migraine. The United States emerged as the leading nation in both publications and citations, with academic Peter Goadsby contributing the highest number of publications. The University of Copenhagen stood out as the institution with the most publications, and Cephalalgia emerged as the most influential journal. The most cited paper identified was \"Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine\" by Jes Olesen, published in the New Engl Med. Keyword frequency analysis revealed prevalent terms such as \"migraine,\" \"CGRP,\" and \"episodic migraine,\" along with emerging topics represented by keywords including \"trial,\" \"monoclonal antibodies,\" \"preventive treatment,\" and \"safety.\"
UNASSIGNED: CGRP is pivotal in migraine pathogenesis, and there is a robust research foundation exploring its role. The US leads in research output on CGRP in migraine. Investigating the mechanism of CGRP and its receptor in migraine remains a key area of interest, particularly focusing on signaling pathways. Future research should target identifying critical therapeutic targets in CGRP antagonist pathways for migraine treatment.
UNASSIGNED: Bibliometric tools including CiteSpace, VOSviewer, etc., were utilized to extract and summarize publications related to CGRP in migraine from the Web of Science Core Collection Database (WOSCC) between 2004 and 2023, as of December 31, 2023. The analysis focused on trends in annual publications, leading countries/regions and institutions, prominent journals and references, influential authors, and high-frequency keywords in the field.
UNASSIGNED: A total of 1,821 articles and reviews involving 5,180 authors from 1,315 organizations across 64 countries were included in the study. These publications were distributed across 362 journals and accumulated 56,999 citations by December 31, 2023. An increasing trend was observed in annual publications on CGRP in migraine. The United States emerged as the leading nation in both publications and citations, with academic Peter Goadsby contributing the highest number of publications. The University of Copenhagen stood out as the institution with the most publications, and Cephalalgia emerged as the most influential journal. The most cited paper identified was \"Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine\" by Jes Olesen, published in the New Engl Med. Keyword frequency analysis revealed prevalent terms such as \"migraine,\" \"CGRP,\" and \"episodic migraine,\" along with emerging topics represented by keywords including \"trial,\" \"monoclonal antibodies,\" \"preventive treatment,\" and \"safety.\"
UNASSIGNED: CGRP is pivotal in migraine pathogenesis, and there is a robust research foundation exploring its role. The US leads in research output on CGRP in migraine. Investigating the mechanism of CGRP and its receptor in migraine remains a key area of interest, particularly focusing on signaling pathways. Future research should target identifying critical therapeutic targets in CGRP antagonist pathways for migraine treatment.
摘要：
■偏头痛是全球公共卫生问题，影响社会和个人福祉。降钙素基因相关肽(CGRP),一种关键的神经肽，对理解偏头痛的发病机制具有重要的研究价值。CGRP受体拮抗剂和靶向CGRP或其受体的单克隆抗体已显示出降低偏头痛频率和严重程度的功效。提出了一种有希望的治疗方法。本研究旨在进行全面的文献计量分析，以分析现状，研究趋势,以及CGRP在偏头痛中的未来方向。
■文献计量工具，包括CiteSpace，VOSviewer,等。,用于从2004年至2023年12月31日的WebofScience核心收藏数据库（WOSCC）中提取和总结与偏头痛中CGRP相关的出版物。分析的重点是年度出版物的趋势,领先的国家/地区和机构，著名的期刊和参考文献，有影响力的作家,和领域中的高频关键词。
■这项研究共纳入1,821篇文章和评论，涉及来自64个国家/地区的1,315个组织的5,180名作者。到2023年12月31日，这些出版物分布在362种期刊上，累计引用56,999篇。在偏头痛CGRP的年度出版物中观察到了增加的趋势。美国在出版物和引文方面都是领先的国家，学术PeterGoadsby贡献了最多的出版物。哥本哈根大学是出版物最多的机构，而脑痛症成为最有影响力的期刊。被引用最多的论文是JesOlesen的“降钙素基因相关肽受体拮抗剂BIBN4096BS用于偏头痛的急性治疗”，发表在《新英语医学杂志》上。关键词频率分析揭示了流行的术语，如“偏头痛，\"\"CGRP,“和”发作性偏头痛，“以及由包括“试用”在内的关键字代表的新兴主题，单克隆抗体，预防性治疗，\"和\"安全。\"
■CGRP在偏头痛发病机制中至关重要，有一个强大的研究基础来探索它的作用。美国在偏头痛CGRP方面的研究成果处于领先地位。研究CGRP及其受体在偏头痛中的作用机制仍然是人们关注的关键领域，特别关注信号通路。未来的研究应着眼于确定用于偏头痛治疗的CGRP拮抗剂途径中的关键治疗靶标。
■文献计量工具，包括CiteSpace，VOSviewer,等。,用于从2004年至2023年12月31日的WebofScience核心收藏数据库（WOSCC）中提取和总结与偏头痛中CGRP相关的出版物。分析的重点是年度出版物的趋势,领先的国家/地区和机构，著名的期刊和参考文献，有影响力的作家,和领域中的高频关键词。
■这项研究共纳入1,821篇文章和评论，涉及来自64个国家/地区的1,315个组织的5,180名作者。到2023年12月31日，这些出版物分布在362种期刊上，累计引用56,999篇。在偏头痛CGRP的年度出版物中观察到了增加的趋势。美国在出版物和引文方面都是领先的国家，学术PeterGoadsby贡献了最多的出版物。哥本哈根大学是出版物最多的机构，而脑痛症成为最有影响力的期刊。被引用最多的论文是JesOlesen的“降钙素基因相关肽受体拮抗剂BIBN4096BS用于偏头痛的急性治疗”，发表在《新英语医学杂志》上。关键词频率分析揭示了流行的术语，如“偏头痛，\"\"CGRP,“和”发作性偏头痛，“以及由包括“试用”在内的关键字代表的新兴主题，单克隆抗体，预防性治疗，\"和\"安全。\"
■CGRP在偏头痛发病机制中至关重要，有一个强大的研究基础来探索它的作用。美国在偏头痛CGRP方面的研究成果处于领先地位。研究CGRP及其受体在偏头痛中的作用机制仍然是人们关注的关键领域，特别关注信号通路。未来的研究应着眼于确定用于偏头痛治疗的CGRP拮抗剂途径中的关键治疗靶标。
